Capture Vascular Continues with New Clinical Cases for its MegaVac Mechanical Thrombectomy System

Capture Vascular, Inc. (Capture) recently completed three successful clinical cases using its proprietary MegaVacTM Mechanical Thrombectomy System-ATK.
 
The first case involved a 42-year-old male patient with a target treatment area of the right leg, above and below the knee. Overall the MegaVacTM Mechanical Thrombectomy System was noted that it worked both easy and well and the procedure was marked successful.
 
The second case involved a 62-year-old female patient with a target treatment area of the left leg above the knee. Again the system was noted as working both easy and well where the procedure was not only successful, but the MegaVacTM Mechanical Thrombectomy System exceeded expectations.
 
The third case involved a 67-year-old male patient with a target treatment area of the left leg, above and below the knee. The MegaVacTM Catheter and ThromboWireTM Clot Retractor both performed well with debris noted in the ThromboWireTM Clot Retractor after removal.
 
Capture will continue to perform clinical cases throughout the coming months as it focuses on adoption of the MegaVacTM Mechanical Thrombectomy System-ATK.
 
The recently expanded device description of the ATK builds off of Capture’s mechanical thrombectomy technology with key features such as centering and securing the occlusion funnel tip position within the vessel, in addition to being able to pass through other lesion disruptive devices through its lumen. With these updates, Capture’s MegaVacTM Mechanical Thrombectomy System-ATK can now provide proximal occlusion, a static work environment, and the removal of emboli and thrombi for even more situations.

“In working through recent clinical experiences we continually received feedback from physicians that they wanted to use Capture’s system as a proximal occlusion conduit for atherectomy systems, CTO crossing wires, balloons and stents,” says Eric Wells, CEO of Capture Vascular. “I’m particularly excited that the team was able to meet our customer’s needs and execute these device advances,” says Wells.
 
Founded in 2013, Capture’s proprietary technology includes the MegaVacTM Catheter with SafeSealTM Technology and the ThromboWireTM Clot Retractor, which makes up the MegaVacTM Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device. 

--

About Capture Vascular, Inc.
Headquartered in Telluride, Colorado, Capture Vascular, Inc. is a Medical Device development company that was founded in May of 2013 to pursue the development and commercialization of innovative medical devices. Capture Vascular’s platform technology is the MegaVacTM Mechanical Thrombectomy System that offers several unique features in one simple, efficient, and effective device. Capture Vascular, Inc. is managed by Telluride Medical Partners LLC. For more information about Capture Vascular and its technology please visit www.capturevascular.com.


About Telluride Medical Partners LLC
Headquartered in Telluride, CO, Telluride Medical Partners LLC was founded in 2016 by Eric Wells and is comprised of business and medical device startup experts and entrepreneurs focused on bringing disruptive medical devices and technologies to market. With a cohort of five medical technologies, Telluride Medical Partners is quickly expanding and serving clients worldwide. For more information visit www.telluridemedicalpartners.com.

Dr. Richard Fulton Steps Down as Chief Medical Officer

Dr. Richard Fulton announced today that he is stepping down from his role as Chief Medical Officer at Telluride Medical Partners.

An esteemed medical practitioner who practiced radiology and interventional radiology for 30 years prior to joining TMP, Dr. Fulton is a prolific inventor with 50-plus issued patents as well as a number of successfully commercialized medical devices including Capture Vascular’s MegaVac Mechanical Thrombectomy System. He has dedicated his post practice life to inventing novel, easy-to-use, and cost-effective devices and products designed to address a wide-range of medical conditions and treatment dilemmas.

“We are grateful to have had Dr. Fulton as part of the TMP team and respect his decision to spend more time with his family”, states Eric Wells, CEO of TMP.

Dr. Fulton will continue to sit on the board for both Capture Vascular and Awestruck Dental, two companies he founded over the last half decade. A true idea-man and passionate inventor, Dr. Fulton will also continue to work on new medical devices outside of TMP.

“We wish Dr. Fulton all of the best of luck with his future endeavors and we thank him for his time serving as Chief Medical Officer at Telluride Medical Partners,” says Wells.

Capture Vascular, Inc. Secures Updated FDA 510(k) Clearance

Capture Vascular Inc. (Capture), a Telluride Medical Partners company, announced today that it has received updated FDA 510(k) clearance that expands the device description for its proprietary MegaVacTM Mechanical Thrombectomy System.

“In working through recent clinical experiences, we continually received feedback from physicians that they wanted to use Capture’s system as a proximal occlusion conduit for atherectomy systems, CTO crossing wires, balloons and stents,” says Eric Wells, CEO of Capture Vascular. “I’m particularly excited that the team was able to meet our customers needs and execute these device advances,” says Wells.

The expanded device description builds off of Capture’s mechanical thrombectomy technology with key features such as centering and securing the occlusion funnel tip position within the vessel and being able to pass other lesion disruptive devices through its lumen. With these updates, Capture’s MegaVacTM Mechanical Thrombectomy System can now provide proximal occlusion, a static work environment, and the removal of emboli and thrombi for even more situations.

“We are confident that Vascular Surgeons, Interventional Cardiologists and Interventional Radiologists will find the system effective and easy-to-use in providing proximal occlusion of antegrade blood flow, thereby reducing the potential for an embolic occurrence while performing highly disruptive peripheral treatments,” says Wells.

Founded in 2013, Capture’s proprietary technology includes the MegaVacTM Catheter with SafeSealTM Technology and the ThromboWireTM Clot Retractor, which makes up the MegaVacTM Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device. For more information about Capture Vascular and its technology please visit www.capturevascular.com.

AngelMD Features Capture Vascular In Startup Spotlight Blog

AngelMD, an equity crowdfunding company that connects physician investors with leading medical startups, featured Capture Vascular as a featured startup company on the angelMD blog.

“The mechanical thrombectomy market is ready for a new technology to replace outdated methods. Devices currently in the market have been used for over a decade and fall short as they are prone to distal embolization, inefficient aspiration, and clogging…”

Read the full spotlight here.

Telluride Venture Accelerator Innovation Showcase

Photo Credit: Telluride Venture Accelerator

Photo Credit: Telluride Venture Accelerator

On July 18, 2017 Telluride Medical Partners was a featured company at the Telluride Venture Accelerator's Innovation Showcase event. The event highlighted up-and-coming companies headquartered in Telluride, CO and was a great opportunity to further expose TMP, its companies, its team, and its technologies to potential investors. Over 50 people attended the event and we received a lot of interest in TMP and its companies.

Medical Device Entrepreneur Robert Whirley Joins Telluride Medical Partners Board of Advisors

Telluride Medical Partners (TMP) is pleased to announce that longtime medical device industry expert and entrepreneur Robert Whirley has joined the TMP Board of Advisors.

“We could not be more thrilled to have Robert Whirley, a medical device leader with 20 years of in-depth medical experience to be part of our Board of Advisors team,” stated Eric Wells, Founder and Chief Executive Officer of TMP.

A longtime medical device consultant, Whirley has worked for successful healthcare companies such as Boston Scientific and TriVascular, Inc., and has demonstrated a proven ability to build teams and take products from concept to global commercialization.

“Whirley has worked with leading biotech medical clients to address key challenges in product development, global regulatory compliance, strategic planning and fundraising for medical device and biotech clients ranging from early-stage ventures to established public companies,” Wells says. “He has strong engineering and communication skills with a thorough understanding of U.S. and European clinical trial and regulatory approval processes, the latter of which will be especially valuable when we take our medical devices and technologies abroad.”

In addition, Whirley has extensive experience in product development, approval strategy, aligning physician inputs with product definition and device durability, and is also the inventor/co-inventor of over 20 issued patents and published applications.

Telluride Medical Partners Secures Contract with Medical Device Company Capture Vascular Inc.

Telluride Medical Partners (TMP) is pleased to announce that it has secured a contract with Capture Vascular Inc. (Capture Vascular), an early stage medical device company that has developed and is commercializing innovative Mechanical Thrombectomy Systems.

“We are thrilled to have Capture Vascular and its platform technology, the MegaVacTM Mechanical Thrombectomy System, as part of the Telluride Medical Partners portfolio,” says Eric Manzanares, Senior Vice President of Sales and Marketing of TMP. “The technology is extremely unique and provides a tremendous amount of utility throughout the vasculature.”

Comprised of proprietary technology that includes the MegaVacTM Catheter with SafeSealTM Technology and the ThromboWireTM Clot Retractor, Capture Vascular’s MegaVacTM Mechanical Thrombectomy System is designed to safely and effectively occlude vessels, encumbering the potential for distal embolization, while removing thrombus and emboli throughout the peripheral and coronary vasculature. The combination of occlusion, disruption and complete removal provides numerous advantages over currently available devices.

“Typical balloon-type occlusion methods today exceed the optimal occlusion pressure as there is no known endpoint for occlusion other than injecting contrast in the vessel (a trial-and-error approach), hence most balloons are inflated beyond the optimal sealing pressure to assure a true seal,” explains Manzanares. “Capture’s MegaVacTM Catheter with SafeSealTM Technology utilizes minimal outward radial force along with the patient’s own blood pressure to create a ‘safe seal’ of the vessel proximally to the target work zone. The ability to arrest distal blood flow and naturally center and anchor allows physicians to work continuously in a static-flow environment without blood flow interference. When you combine this unique and effective occlusion capability with efficient aspiration and the ThromboWireTM Clot Retractor, you have a device with tremendous utility.”

Capture Vascular has a strong portfolio of 30 patents with protection until 2031, and both the MegaVacTM Catheter with SafeSealTM Technology and ThromboWireTM Clot Retractor devices have received FDA 510(k) clearance for thrombectomy and temporary occlusion of blood flow.

“This is a really exciting time for Capture,” says Manzanares. “Last fall, renowned cardiologist Jeffrey Chambers, MD, of the Metropolitan Heart and Vascular Institute performed several clinical experience cases in Coon Rapids, Minn.. The results were overwhelmingly positive and we are eager to get the first devices out to market.”

Capture Vascular’s first commercialized units specific to ATK peripheral treatment will be available next month in the United States. “Capture Vascular currently has distribution partners within the Pacific Northwest, Michigan and Ohio, as well as several others near completion,” says Manzanares. “We have also negotiated distribution agreements with groups outside of the United States, including in the Netherlands, Italy, South America and most of Asia.”

Capture Vascular is in the process of finalizing its coronary solution, and is also developing a device for treatment of deep-vein thrombosis (DVT) and a separate device for treatment of pulmonary embolism (PE). The coronary solution is expected to be available in Q3 of 2017 and the DVT and PE solutions should be available commercially in 2018-19.

To learn more about Capture Vascular and its technology, visit: www.capturevascular.com.

Vatrix Medical Shareholders Vote To Merge with Nectero Medical Inc.

 
Nectero Logo.png
 

Nectero Medical Inc. (Nectero Medical), established by medical device industry experts Bruce Roberts and Jack Springer, along with Telluride Medical Partners’ Founder and CEO, Eric Wells, has officially merged with Vatrix Medical, a company that developed a technology to prevent and treat vascular aneurysms, a fatal disease that causes the walls of blood vessels to expand, weaken and ultimately rupture.

“We are pleased to announce that in early May 2017 the Vatrix Medical shareholders passed the vote and Nectero Medical will now oversee the technology under the management of Telluride Medical Partners,” says Wells, founder and Chief Executive Officer of Telluride Medical Partners. “The team has initiated a development plan and is eager to bring the technology to market,” stated Wells.

Currently the sole treatment for abdominal aortic aneurysms (AAA) is surgical intervention, and only five percent of patients are candidates for this high-risk procedure. In addition, 600,000+ patients are anxiously living with risk of fatal rupture and greater than two million patients worldwide are actively promoting free screening programs that will expand the patient base.

“Disruptive and unique, Nectero Medical’s vascular procedure called AAvert includes a patented polymer called Pentagalloyl glucose, or PGG, that is derived from plant polyphenols and helps to stop abdominal aortic aneurism growth to ultimately improve tissue strength. An industry game changer, this minimally invasive procedure can change the treatment paradigm and quality of life for more than 600K patients,” says Wells.

With a combined portfolio of 21 patents, next steps for Nectero Medical includes gathering clinical safety and efficacy data as well as securing its CE mark to sell outside of the United States.

Telluride Medical Partners Acquires Three Novel Medical Device Companies

Telluride Medical Partners announced today that it has acquired three novel medical device startup companies within the sleep, oncology and mechanical ventilation industries.

“We couldn’t be more thrilled to have these companies under the Telluride Medical Partners portfolio,” says Eric Wells, Founder and Chief Executive Officer of Telluride Medical Partners. “Each of these companies is both disruptive and revolutionary within their respected fields, and we can’t wait to take each to their next level of growth”, says Wells.

The cohort of companies and their technology is incredibly impressive, to say the least.

Chrona Sleep’s proprietary sleep-sensing device applies acoustic neuromodulation to enhance sleep and neuroplasticity, targeting more than 113 million sleep-deprived Americans. The market is expected to experience explosive growth with projections of 248 million devices sold worldwide in 2017 and upwards of one billion in 2020.

Lighthill Medical, Inc. is developing a family of catheters for the delivery of oncology agents for image-guided, minimally invasive interventional procedures. Over 700,000 individuals globally are diagnosed with liver cancer alone every year and 85% are non-resectable, which equates to 573,000 individuals who are potential candidates for targeted therapy. This represents a $340M market opportunity.

Utilizing a proprietary open-loop algorithm along with additional sensor inputs across the thoracic cavity, Nespiro has developed a new data-driven solution for mechanical ventilation weaning and prediction of post-extubation complications. As an accessory product business model, Nespiro’s market is an estimated $192M in the U.S. on disposable components alone.

With an experienced team comprised of business entrepreneurs and medical device startup experts, Telluride Medical Partners prides itself in investing in creative opportunities to provide value-added operational and managerial leadership, strategic business planning and the necessary capital to grow prosperous medical device companies while realizing each company's unique business objectives.

“Smart medical strategy is our mission,” says Wells. “We are excited to grow and take these companies to full commercialization or an early exit through acquisition.”

TMP Merges with MediCoventures to Further Accelerate Mission of Building Successful Medical Device Startup Companies

Telluride Medical Partners is pleased to announce its merger with MediCoventures, a successful medical device venture firm based in Phoenix, Arizona since 2010.

The merger blends the corporate and investment experience of Telluride Medical Partners with the medical technology incubation expertise of MediCoventures. The combination of resources will allow Telluride Medical Partners to further accelerate their mission of building successful medical device startup companies.

“We are thrilled to join forces with MediCoventures and add medical device startup experts Aaron Call and Kelvin Ning to the Telluride Medical Partners team,” says Telluride Medical Partners CEO Eric Wells.

Call and Ning have worked at or founded numerous early-stage medical device companies and have worked on over 400 new medical technologies while at MediCoventures. Collectively, with almost two decades of startup medical device expertise, Call and Ning will manage day-to-day operations and bring medical device products to market.

“Growing medical device startups is a passion for us,” stated Call. “Having the opportunity to expand on that passion right here in Arizona by partnering with Telluride Medical Partners is such a great opportunity.”